Trial Profile

Phase II randomized study evaluating the efficacy of panitumumab (VEctibix) and Trifluridine-Tipiracil (LOnsurf) in pretreated RAS wild type metastatic colorectal cancer patients: the VELO trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2023 Results of individual pooled data of 4 studies (CAVE, VELO, CRICKET and CHRONOS) assessing Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer, presented at the 48th European Society for Medical Oncology Congress.
21 Jan 2023 Primary endpoint (PFS: defined as the time from randomization to the earliest documented disease progression or death due to any cause) has been met, according to Results presented at the 2023 Gastrointestinal Cancers Symposium.
21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com